Eileen F Dunne1, Shannon Stokley2, Weiwei Chen2, Fangjun Zhou2. 1. National Center for HIV, Viral Hepatitis, STD and TB Prevention, CDC, Atlanta, Georgia. Electronic address: dde9@cdc.gov. 2. National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia.
Abstract
PURPOSE: Information on vaccine utilization from a variety of sources is useful to give a status of the vaccine program and define opportunities to improve uptake. We evaluated MarketScan Commercial Claims and Encounters database on human papillomavirus (HPV) vaccine initiation and completion of all three doses among girls/women from 2006 to 2012. METHODS: Data were obtained from the 2006-2012 MarketScan Commercial Claims and Encounters database. The study population included female enrollees aged 11-26 years who were continuously enrolled in the same private insurance plan from 2006 to 2012 (n = 407,371). We evaluated overall and yearly vaccine initiation and completion, demographic characteristics associated with vaccine initiation, clinical visits in which vaccine was given, and missed opportunities for vaccination. RESULTS: By the end of 2012, 36.9% of females aged 11-26 years had received at least one HPV vaccine dose. Vaccination coverage was highest among females aged 17-18 years (49.3%) and aged 15-16 years (43.1%) and lowest among females aged 11-12 years (16.8%). Between 2007 and 2012, 96.1% of the 246,192 unvaccinated females had at least one missed opportunity (a heath care visit without HPV vaccine administered). CONCLUSIONS: Over a 6 year period, HPV vaccine initiation was lowest in the girls aged 11-12 years. Importantly, most (96.1%) unvaccinated females had at least one missed vaccination opportunity, and providers and health systems should focus efforts on using existing visits for vaccination. Published by Elsevier Inc.
PURPOSE: Information on vaccine utilization from a variety of sources is useful to give a status of the vaccine program and define opportunities to improve uptake. We evaluated MarketScan Commercial Claims and Encounters database on human papillomavirus (HPV) vaccine initiation and completion of all three doses among girls/women from 2006 to 2012. METHODS: Data were obtained from the 2006-2012 MarketScan Commercial Claims and Encounters database. The study population included female enrollees aged 11-26 years who were continuously enrolled in the same private insurance plan from 2006 to 2012 (n = 407,371). We evaluated overall and yearly vaccine initiation and completion, demographic characteristics associated with vaccine initiation, clinical visits in which vaccine was given, and missed opportunities for vaccination. RESULTS: By the end of 2012, 36.9% of females aged 11-26 years had received at least one HPV vaccine dose. Vaccination coverage was highest among females aged 17-18 years (49.3%) and aged 15-16 years (43.1%) and lowest among females aged 11-12 years (16.8%). Between 2007 and 2012, 96.1% of the 246,192 unvaccinated females had at least one missed opportunity (a heath care visit without HPV vaccine administered). CONCLUSIONS: Over a 6 year period, HPV vaccine initiation was lowest in the girls aged 11-12 years. Importantly, most (96.1%) unvaccinated females had at least one missed vaccination opportunity, and providers and health systems should focus efforts on using existing visits for vaccination. Published by Elsevier Inc.
Authors: Jessica A Kahn; H Paul Cooper; Susan T Vadaparampil; Barbara C Pence; Armin D Weinberg; Salvatore J LoCoco; Susan L Rosenthal Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-08 Impact factor: 4.254
Authors: Jennifer L Young; Ruth G Bernheim; Jeffrey E Korte; Mark H Stoler; Thomas M Guterbock; Laurel W Rice Journal: J Pediatr Adolesc Gynecol Date: 2011-09-09 Impact factor: 1.814
Authors: Sharon J M Kessels; Helen S Marshall; Maureen Watson; Annette J Braunack-Mayer; Rob Reuzel; Rebecca L Tooher Journal: Vaccine Date: 2012-04-03 Impact factor: 3.641
Authors: Laurie D Elam-Evans; David Yankey; Jenny Jeyarajah; James A Singleton; Robinette C Curtis; Jessica MacNeil; Susan Hariri Journal: MMWR Morb Mortal Wkly Rep Date: 2014-07-25 Impact factor: 17.586
Authors: Julia M L Brotherton; Mark Jit; Patti E Gravitt; Marc Brisson; Aimée R Kreimer; Sara I Pai; Carole Fakhry; Joseph Monsonego; Silvia Franceschi Journal: Int J Cancer Date: 2016-03-22 Impact factor: 7.396
Authors: Summer Sherburne Hawkins; Krisztina Horvath; Jessica Cohen; Lydia E Pace; Christopher F Baum Journal: Cancer Causes Control Date: 2021-04-17 Impact factor: 2.506
Authors: Julia Warner Gargano; Ina U Park; Marie R Griffin; Linda M Niccolai; Melissa Powell; Nancy M Bennett; Michelle L Johnson Jones; Erin Whitney; Manideepthi Pemmaraju; Monica Brackney; Nasreen Abdullah; Mary Scahill; Rebecca M Dahl; Angela A Cleveland; Elizabeth R Unger; Lauri E Markowitz Journal: Clin Infect Dis Date: 2019-04-08 Impact factor: 9.079
Authors: Stephanie A Irving; Holly C Groom; Shannon Stokley; Michael M McNeil; Julianne Gee; Ning Smith; Allison L Naleway Journal: Acad Pediatr Date: 2018-03 Impact factor: 3.107
Authors: Jennifer L St Sauver; Lila J Finney Rutten; Jon O Ebbert; Debra J Jacobson; Michaela E McGree; Robert M Jacobson Journal: Prev Med Date: 2016-02-28 Impact factor: 4.018
Authors: Tanya L Kowalczyk Mullins; Susan L Rosenthal; Gregory D Zimet; Lili Ding; Charlene Morrow; Bin Huang; Jessica A Kahn Journal: J Adolesc Health Date: 2017-12-02 Impact factor: 5.012
Authors: Carlos R Oliveira; Robert M Rock; Eugene D Shapiro; Xiao Xu; Lisbet Lundsberg; Liye B Zhang; Aileen Gariepy; Jessica L Illuzzi; Sangini S Sheth Journal: Am J Obstet Gynecol Date: 2017-12-06 Impact factor: 10.693